Jul 5, 2024, 01:49
Highlights of the RADIOSA phase II trial presented at ESTRO24
European Society for Radiotherapy and Oncology (ESTRO) shared a paper on LinkedIn:
“Highlights of the RADIOSA phase II trial presented at ESTRO24: SBRT + short-term ADT significantly improves outcomes in oligorecurrent hormone-sensitive prostate cancer patients.
Report by Simon Spohn.”
Read further.
Source: ESTRO/LinkedIn